Artesunate intravenous - US Army Medical Material Development Activity/Walter Reed Army Institute of Research

Drug Profile

Artesunate intravenous - US Army Medical Material Development Activity/Walter Reed Army Institute of Research

Alternative Names: Artesunate intravenous project - MMV00/1013; Artesunate IV; Artesunate IV project - MMV00/1013; Intravenous artesunate; IV artesunate; Nuartez

Latest Information Update: 02 Nov 2016

Price : $50

At a glance

  • Originator U.S. Army Medical Materiel Development Activity; Walter Reed Army Institute of Research
  • Developer Sigma-Tau Pharmaceuticals; Walter Reed Army Institute of Research
  • Class 3-ring heterocyclic compounds; Antimalarials; Artemisinins; Small molecules; Succinates
  • Mechanism of Action Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malaria
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malaria

Most Recent Events

  • 07 Aug 2015 Preparations for NDA filing in USA are ongoing
  • 30 Apr 2007 Phase-II clinical trials in Malaria treatment in Africa (IV)
  • 30 Apr 2007 Phase-II clinical trials in Malaria treatment in Thailand (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top